chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Body pain; Some headache; Fever; Soreness of arm; This is a spontaneous report received from a contactable consumer (parent). A 17-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: LW0161), via an unspecified route of administration, administered in arm left on 16Apr2021 at 09:30 (age at vaccination 17-year-old) as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were reported as none. No additional administered vaccines were reported. Prior vaccinations within 4 weeks and adverse events following prior vaccinations were reported as none. Family medical history relevant to adverse events was reported as none. On 16Apr2021, the patient experienced soreness of arm. On 17Apr2021, the patient experienced body pain, some headache and fever. The patient underwent lab tests and procedures which included body temperature: 100 degrees on 17Apr2021 and 102 degrees on 22Apr2021. Adverse event did not require a visit to emergency room or physician office. Reported that the patient's fever was very high this morning, 22Apr2021. Parent reported that the patient's temperature was 102 on morning of call, 22Apr2021 and reported that the patient has missed 2 days of school. Reporter inquired if it was normal to have a fever for so many days after the COVID-19 vaccine. Patient reported that she no longer has a headache. Patient reported that the headache lasted from 17Apr2021 until probably the next day, 18Apr2021, or maybe Monday 19Apr2021. Patient reported that the headache did not last for very long. Patient reported that the body pain comes and goes with the fever. Patient initially reported that the body pain was about the same or maybe worse, but then stated that because her fever was getting higher, the body pain was worse. Patient reported that her second dose of the COVID-19 vaccine is scheduled for 12May2021. Therapeutic measures were taken as a result of the events which included treatment with Motrin every 4 to 6 hours, sometimes alternating with Tylenol. The outcome of the events (body pain, fever) was not recovered, event (Soreness of arm) was recovered on 17Apr2021, and event (headache) was recovered on 19Apr2021.  No follow-up attempts are possible. No further information is expected.
Mild induration at the vaccine site a few hours after vaccination lasting 36 hours. Mild-moderate induration and pruritis, splotchy reddness and ache  distal and caudal to the vaccine site starting about 1 week post vaccination. So far it has lasted 24 hours and not gotten better or worse.  Improves slightly when ice is applied.
Around 5 pm on 1/26/21 developed temp of 102.4 that lasted for 36 hours.  During this time also had fatigue and aches. intermittent left face numbness.  Symptoms resolved after 36 hours but at times still very mild left face numbness.
Pt. received first dose of Pfizer COVID19 vaccine on 2/10/21, 2nd dose on 3/3/21, and was subsequently admitted to the hospital on 4/6/21 and found to have COVID-19
From telephone contact from reporting nurse stated that a 22-year-old female patietn received a TD Adult and MMR vaccination on 6/11/01. The patient developed pain and stiffness in her shoulder joint. Patient was seen at physician's office, symptoms unresolved.
16 yr old patient lost consciousness while siting in observation area after received her 2nd dose of pfizer COVID vaccine. She fell from chair to the flood. Her father was siting beside her but did not see which part of her body hit the floor first.  Look for injury and no injury was found. Positioned patient supine with legs elevated. VS taken which was stable: P88; resp 18;BP 118/72 and O2 Sat 100%. Patient woke up once laying supine. She states she saw a drop of blood from the vaccination site and she blacked out. Patient feel totally recovered. She was assisted back to her chair. Water and snack offered to her. She was observed for additional 15minutes and then left with her father. Her father was advised to take patient to ER if increased headache, dizziness, or altered mental status with understanding.
Subsequently post vax, the pt experienced dizziness, a severe headache, weakness, was sleepy, had a hot sensation on his back, and stomach pain. The pt sought unspecified medical treatment. Additionally, it was noted that two pts experienced similar experiences after vax with hepatitis b.
Hour 1-3 Intense nausea and chills Hour 2-5 Headache pain at injection site Hour 3-7 Intense Headache and pain radiated up trapezius into neck and side of head Hour 7 Took 400mg Ibuprofen, symptoms decreased significantly except for pain and restriction of movement in left arm and moderate headache.
Fell to floor after getting vaccines. Pt was pale and staring straight ahead with 2 shakes of head. RN was able to arouse pt and handed pt to father. After about 1min child became unresponsive, pale with cyanotic lips again. Turned head to right with 2-3 slight shakes. Episode lasted 3-4 seconds. Able to arouse again. No incontinence. No post ictal behavoir. Oriented to father. Ambulance arrived and transported pt to hospital.  HR 84 RR 32
No immediate reaction to the shot on 5/15/21.  2 weeks later 5/29/21 noticed music suddenly sounded different.   Audiogram 6/1/21 confirmed 10-20dB loss in left ear on most frequencies.  ENT diagnosed with Sudden Sensorineural Hearing Loss and started on prednisone.  6/2/21 Audiogram showed 5-15dB improvement in most frequencies <8khz but 30-50dB loss in 12.5-16khz range.  No tinnitus reported.  No change in hearing or tinnitus since then.
About 12 hours after the second dose of the Moderna COVID-19 vaccine, I became chilled and achy with a fever of 101. I had a fitful night and woke in the morning with a splitting headache, the worst I ever had. I took Excedrin throughout the day  and stayed in bed with a fever that spiked to 103 in the afternoon and continued with aches and a headache. The bout lasted about 24 hours and then I felt fine with a bit of brain fog.
3 days p/vax pt exp arthralgia;f/u info was recv 6JAN97;pt exp arthralgia in all joints;it was worse in the small joints;@ the time of f/u arthralgia persisted but was not as severe;
Last week before going to the doctor my well woman visit my heart beat was well over 100 for a few days but I felt fine. I didn't feel good but I didn't feel bad. This is not the normal thing because my bp usually runs 118/78 but at the doctor's last week it was 152/81. She has me going to see the Cardiologist next week. I was given beta blockers and the heart rate is down now.
REDNESS AND SWELLING AROUND INJECTION SITE; PAIN AND HARDNESS AROUND INJECT SITE; DOLD AND FLU LIKE SYMPTOPMS
Pt recvd 16SEP93 15 hrs later, pt presented to ER w/fever of 100.6, hypertensive 140/100 & lt arm pain that traveled from inject site to lt shoulder; pt hospitalized;
Patient felt arm got swollen and started experiencing pain.  She went to emergency clinic when pain continued. Was told that it was probably a reaction to vaccine and for her to take ibuprofen and put warm compression.  Patient says as of 11/5/2012 pain continues and she is now she is feeling numbness in 3 of her fingers and that her back hurts.  Says Ibuprofen does not relieve pain.
how long soreness may persist after shingrix vaccination; This case was reported by a consumer via interactive digital media and described the occurrence of pain in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was not recovered/not resolved.   It was unknown if the reporter considered the pain to be related to Shingrix.  Additional details were provided as follows: The age at the vaccination was not reported. The age group was selected as an adult, however it was selected as an adult as per vaccine indication. The reporter wanted to know how long soreness might persist after Shingrix vaccination.
COVID-19; COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 28-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13Apr2021 at 12:15 as dose 1, single (Batch/Lot number: unknown), in left arm, on 04May2021 at 12:15 as dose 2, single (Batch/Lot number: unknown), in left arm and on 16Nov2021 at 17:15 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Past drug history included: Known allergies: no, reaction(s): "Drug Allergy". The following information was reported: SUSPECTED COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of suspected covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Soreness at injection site and around it, 3" diameter. Body aches, joint pain, headache, chills and slight fever
Body ache; Chills; Fever; Headache; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 30Mar2021 at 11:30 (at the age of 24-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food or other products. The patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021, the day of vaccination, the patient experienced sore arm and headache. On 12Apr2021 at 00:00, the patient started to experience body ache, headache, chills and fever. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On an unknown date, the patient underwent SARS-CoV-2 test (mouth swab) and the result was negative. The clinical outcome of events sore arm, body ache, headache, chills and fever were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Patient reported that immediately after receiving the vaccine she felt lightheaded, dizzy, like she might pass out. She felt as though her throat was more swollen and she had difficulty swallowing.   She had no hives, shortness of breath, or difficulty breathing. No myalgias, sore throat, cough, or wheezing.
hives and welts along the back; she had rashes and welts on the front upper side; This is a spontaneous report from a contactable consumer (parent). A 17-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on 12Apr2021 at 14:00 as single dose for COVID-19 immunization. Medical history and concomitant medications were not provided. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on 15Mar2021 as single dose for COVID-19 immunization and getting a positive Covid test on 29Mar2021. On 13Apr2021 about 21:30, so more than 24 hours later second dose , patient developed hives and welts along the back of her body, got the rashes on her back, patient was given diphenhydramine hydrochloride (BENADRYL) at night and then she woke up around 6 o' clock in the morning, she had rashes and welts on the front upper side, the back is gone, rashes are on the front upper side, the reporting consumer asked was that reaction to the vaccine or should they contact Dermatitis. Outcome of the events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Pain from the elbow to the shoulder; Rash on back and stomach; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Pain from the elbow to the shoulder) and RASH (Rash on back and stomach) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, the patient experienced ARTHRALGIA (Pain from the elbow to the shoulder) and RASH (Rash on back and stomach). At the time of the report, ARTHRALGIA (Pain from the elbow to the shoulder) and RASH (Rash on back and stomach) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Treatment included Tylenol.
Numb in half of face and body. Fever 102. Aches. Cold sweats and chills.  Headache. Tunnel vision.
Patient stood up and was immediately dizzy. Patient stated "i'm dizzy and my mouth feels funny". Able to speak full sentences. heart rate 88, respiratory rate 18, able to swallow, skin warm and dry. Patient was assisted to wheelchair and escorted to the emergency department. Report given to ER nurse.
went to ED c/o chest pain, Pain was non-radiating, intermittent substernal aching. It improved with sublingual nitroglycerin and PO ASA 324mg. Mild SOB was noted. No syncope reported. After arrival to the ED and administration of the above meds, symptoms improved. This AM he described mild worsening SOB during his stress test and an episode of chest tightness shortly thereafter which has now resolved.   He also reports anxiety about his stress test result. A 1/2019 stress test was a normal, low risk study. Today's stress test was read as an intermediate risk study with a medium-sized fixed perfusion defect suggestive of infarction, with associated mild hypokinesis.
Information regarding Flu Mist was received from a healthcare professional regarding her 4 year old son who experienced accidental exposure and developed a fever and dry cough. The mother, a pharmacist, reported that she administered the Flumist to patients in November, 2003. Two days later, she developed a cough. Three days after she developed a cough, her son developed fever and a dry cough. The mother reported that her 8 year old son also developed fever and cough at the same time. Neither the sons nor his mother received Flumist. Related cases: See HQWYE460108DEC03, and HQWYE460208DEC03. No additional info was available at the time of this report.
Fever up to 102 F approx 15-25 hours post vaccination.; This is a spontaneous report from a contactable Nurse (the patient).  A 32-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE Ek9231, expiration date unknown) via an unspecified route of administration on 06Jan2021 at 18:00 (at the age of 32-years-old), at an unspecified dose in the left arm for COVID-19 vaccination.  Medical history was reported as "none." The patient had no allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient was not pregnant at the time of vaccination. The patient was administered the vaccine at a workplace clinic. Historical vaccinations included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number EH9899, expiration date unknown ) via an unspecified route of administration on 16Dec2020 18:00  (at the age of 32-years-old), at an unspecified dose in the left arm for COVID-19 vaccination. Concomitant medication included levonorgestrel (MIRENA). The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced fever up to 102 farenheit approximately fifteen to twenty-five hours post vaccination beginning on 07Jan2021 at 09:00. Treatment information was not provided. The clinical outcome of pyrexia was reported as recovered on an unspecified date in Jan2021. It was also reported that since the vaccination the patient had not been tested for COVID-19.
COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) had resolved.            No concomitant medications were reported.  No treatment medications were reported.  The reporter assessed the event as possibly related to Moderna vaccine and as not reasonably possible with Humira.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
This spontaneous report as recived from a nurse practitioner refers to a patient of unknown age and gender. On 10-NOV-2014 the patient received improperly stored RECOMBIVAX HB (lot#, dose, route not reported, strength 10mcg/1.0ml). Concomitant medications were not provided. No adverse symptoms were reported. The temperature excursion with RECOMBIVAX HB was found to be supported with in-house stability data. Additional information has been requested.
Meets vital records criteria. COVID listed as COD on death certificate.  DIDI COD: ASCVD, DMII, Possible COVID19. The decedent was discovered unresponsive in bed 10/11/21. Pt medical hx: hypertension, diabetes, and a kidney transplant 10 years ago. Pt's daughter had tested positive for COVID the day before and the decedent had been coughing more than usual prior to her death.
Moderna COVID-19 Vaccine   adverse events: low-grade fever, chills, headache, fatigue, muscle weakness, malaise, runny nose, exhaustion, joint pain  treatment: ibuprofen, acetaminophen, long periods of rest, fluids  outcomes: resolved on it's own after about 36 hours.
Chills, fever, full-body muscle/joint aches, headache for 36 hours. After 36 hours, fever subsided and headache and back ache persisted for a few more hours, although less severe. After 41 hours, almost all symptoms gone.
injection site for second dose was defiinitely more sore; had flu like symtoms for 24 hours; This case was reported by a consumer via interactive digital media and described the occurrence of influenza-like symptoms in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms and injection site pain. On an unknown date, the outcome of the influenza-like symptoms was recovered/resolved and the outcome of the injection site pain was not recovered/not resolved.   It was unknown if the reporter considered the influenza-like symptoms and injection site pain to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The injection site for 2nd dose was definitely more sore and had flu like symptoms for 24 hours. The localized pain at the injection site was much worse (could have been the shooter). But the flu like symptoms were not as bad. The follow up was not required. This is 1 of the 3 linked cases reported by the same reporter.
1/16 injection site was extremely sore and disturbed my sleep.  1/17 the soreness was improving.  There was a small rash 1/21.  1/23 the rash got heated and very itchy and I could not sleep.  I applied Biofreeze.   The rash is the same but irritation has calmed down.
Fever over 102ºF, extreme chills (before presence of fever), body aches and soreness at injection site.
Patient reports severe arm paint and limited range of motion beginning 4 hours after immunization and progressively worsen 8 hours after.
Arm pain and swelling from shoulder area through elbow.  Arm swelling resulted in increase in arm curcumference by at least 4 inches.  Please note the patient had received the pneumococcal vaccine in 2008 and again in November 2013 and again in 2014.
Day after vaccines, a little less active and a little more spitty.  Then the next day, poor feeding, lethargic, and pale.  Cool and had a low temp at home of 96.5.  Seen in our clinic with a temp of 96.5 and sent to the ED.
some of the product came out and ran down his arm/backflow after administration; some of the product came out and ran down his arm; A spontaneous report was received from a 29-year-old male nurse who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced backflow after the administration, and some of the product came out and ran down his arm.    The patient's medical history was not provided. Concomitant product use was not provided by the reporter.   The patient received their first of two planned doses of mRNA-1273 on an unknown date.   On 21 Jan 20201, the patient received their second of two planned doses of mRNA-1273 (Lot 029L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.   The patient reported that there was backflow after the administration, and some of the product came out and ran down his arm.  No treatment information was provided.   The patient received both scheduled doses of mRNA-1273 prior to the event, therefore action taken with the drug in response to the event is not applicable.   The outcome of the event, experienced backflow after the administration, and some of the product came out and ran down his arm, was considered resolved on 21 Jan 2021.; Reporter's Comments: This case concerns a 29-year old White, male nurse patient. The patient's medical history and concomitant medications were not provided. The patient experienced a non serious event of some of the product came out and ran down his arm/backflow after administration. The event occurred on the same day as the planned second dose of the mRNA-127 administration, with no reported AEs.
shingles, having them, shots help with pain/ suspected vaccination failure; shingles; pain; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a 68-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure, shingles and pain were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 11-JUL-2022 Reporter's Comment: This case was reported by a consumer via interactive digital media. The reporter stated he/she urge you to get vaccinated even though you have shingles now. The patient stated that in his 68 years of having them they did not ever go away completely but the shots help with the pain. Additional supportive information This case was considered as suspected vaccination failure the details regarding completion of primary vaccination schedule time to onset and laboratory confirmation of shingles was not provided.